AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34403608 — intervention group
Group type: COMPARATOR
Intervention: Verbally informed
Number of subjects: 102
Study 35171836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical laminoplasty (LP)
Number of subjects: 10834
Study 35171836 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cervical laminectomy and fusion (LF)
Number of subjects: 10834
Study 35171836 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion (mACDF)
Number of subjects: 10834
Study 35171836 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical corpectomy and fusion (ACCF)
Number of subjects: 10834
Study 35171836 — intervention group
Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 10834
Study 35123469 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted treatment decision strategy including advice from a treatment algorithm
Number of subjects: 230
Study 33784968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric derisomaltose (FDI)) 1000 mg
Number of subjects: 54
Study 33784968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 33784968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric derisomaltose (FDI))
Number of subjects: 54
Study 35293508 — intervention group
Group type: EXPERIMENTAL
Intervention: G1: 1100 μg F/g, pH 4.5 (n = 76)
Number of subjects: 228
Study 35293508 — intervention group
Group type: EXPERIMENTAL
Intervention: G2: 750 μg F/g, pH 4.5 (n = 74)
Number of subjects: 228
Study 35293508 — intervention group
Group type: EXPERIMENTAL
Intervention: G3: 1100 μg F/g, pH 7.0 (n = 78)
Number of subjects: 228
Study 35293508 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 228
Study 33704351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2 mg/0.05 mL at baseline, 4 weeks, and 8 weeks, as needed from 12 weeks onward)
Number of subjects: 120
Study 33704351 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 120
Study 33704351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 120
Study 32337841 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical plan using a 5-mm expansion of an ITV that encompassed all three GTVs from each of the three ABC-CTs
Number of subjects: 44
Study 32337841 — intervention group
Group type: EXPERIMENTAL
Intervention: Research plan using a 5-mm expansion of the GTV from only ABC1-CT to create PTV
Number of subjects: 44
Study 35584738 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 70
Study 35584738 — intervention group
Group type: COMPARATOR
Intervention: Standard care wait-listed control group
Number of subjects: 70
Study 33206182 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection
Number of subjects: 90
Study 33206182 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 90
Study 35416797 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARISMA counseling intervention
Number of subjects: 407
Study 35416797 — intervention group
Group type: COMPARATOR
Intervention: Standard of care counseling support and referrals
Number of subjects: 407
Study 33554371 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Deficit (WD) + Medium Irradiance (MI)
Number of subjects: 0
Study 33554371 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-Watered (WW) + Higher Irradiance (HI)
Number of subjects: 0
Study 33554371 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Deficit (WD) + Higher Irradiance (HI)
Number of subjects: 0
Study 33330303 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training Group (ETG; n = 35)
Number of subjects: 108
Study 33330303 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training Group (ETG; n = 10 with regular adherence)
Number of subjects: 108
Study 33330303 — intervention group
Group type: COMPARATOR
Intervention: Reference Group (REF; n = 34)
Number of subjects: 108
Study 35319484 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB
Number of subjects: 242
Study 35319484 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB+
Number of subjects: 242
Study 35319484 — intervention group
Group type: EXPERIMENTAL
Intervention: PRINT
Number of subjects: 242
Study 32513231 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Nitazoxanide
Number of subjects: 86
Study 32513231 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 86
Study 34000834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2 grams intravenous)
Number of subjects: 254
Study 34000834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching intravenous)
Number of subjects: 254
Study 33151364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Bearing (MB) total knee arthroplasty (TKA)
Number of subjects: 160
Study 33151364 — intervention group
Group type: COMPARATOR
Intervention: Fixed Bearing (FB) total knee arthroplasty (TKA)
Number of subjects: 160
Study 32929109 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic inhaler monitoring devices
Number of subjects: 211
Study 34961793 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 34961793 — intervention group
Group type: COMPARATOR
Intervention: Esaxerenone
Number of subjects: 0
Study 33234846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for 4 cycles followed by nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity or a maximum of 48 weeks.
Number of subjects: 754
Study 33234846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 754
Study 32621817 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) for undifferentiated-type EGC
Number of subjects: 175
Study 32621817 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD) for differentiated-type EGC
Number of subjects: 175
Study 33576394 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational handout detailing U.S. Food and Drug Administration‐recommended ways to properly dispose of leftover opioids (n=188)
Number of subjects: 499
Study 33576394 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational handout and a drug disposal kit with instructions on its use (n=170)
Number of subjects: 499
Study 33576394 — intervention group
Group type: COMPARATOR
Intervention: No intervention (n=141)
Number of subjects: 499
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime eye rubbing
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye rubbing in the morning
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye rubbing in eyes with the steepest keratometry
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergy
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Red eyes in the morning
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping on stomach/sides
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping on the same side as the steepest keratometry
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime eye rubbing (multivariate model)
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye rubbing in the morning (multivariate model)
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye rubbing in the steepest eye (multivariate model)
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping on stomach/sides (multivariate model)
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping on the steepest side (multivariate model)
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye rubbing (univariate analysis in UHAKC group)
Number of subjects: 33
Study 32524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping position (univariate analysis in UHAKC group)
Number of subjects: 33
Study 34119716 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-acupressure via a patient-designed mobile app and hand-held device for 6 weeks
Number of subjects: 165
Study 34119716 — intervention group
Group type: COMPARATOR
Intervention: Sham app and device for 6 weeks
Number of subjects: 165
Study 34119716 — intervention group
Group type: COMPARATOR
Intervention: No care group
Number of subjects: 165
Study 33472773 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Safety Guide for Primary Care (PSG-PC)
Number of subjects: 120
Study 32441668 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek 400 mg/d
Number of subjects: 57
Study 32441668 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek 500 mg/d
Number of subjects: 57
Study 32441668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 35138350 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal secondary prevention
Number of subjects: 1807
Study 35138350 — intervention group
Group type: COMPARATOR
Intervention: Missing one or more recommended medications
Number of subjects: 1807
Study 36388925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulmus macrocarpa Hance extract (UME) 500 mg (two capsules per day)
Number of subjects: 80
Study 36388925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch, two capsules per day)
Number of subjects: 80
Study 32178787 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Compression (MC)
Number of subjects: 238
Study 32178787 — intervention group
Group type: COMPARATOR
Intervention: Closure Pad (CP)
Number of subjects: 238
Study 35766959 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 75
Study 35766959 — intervention group
Group type: COMPARATOR
Intervention: Thoracic Paravertebral Block (TPVB)
Number of subjects: 75
Study 35766959 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ESPB and TPVB (comb-group)
Number of subjects: 75
Study 35766959 — intervention group
Group type: COMPARATOR
Intervention: TPVB
Number of subjects: 75
Study 35766959 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPB
Number of subjects: 75
Study 34961418 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 132
Study 34961418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 32471494 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 132
Study 32471494 — intervention group
Group type: COMPARATOR
Intervention: Low-flow nasal cannula
Number of subjects: 132
Study 35246497 — intervention group
Group type: EXPERIMENTAL
Intervention: iVAPS
Number of subjects: 30
Study 35246497 — intervention group
Group type: COMPARATOR
Intervention: ST
Number of subjects: 30
Study 36168678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore-Tex® thyroplasty with prior injection laryngoplasty (IL)
Number of subjects: 45
Study 36168678 — intervention group
Group type: COMPARATOR
Intervention: Gore-Tex® thyroplasty without prior injection laryngoplasty (IL)
Number of subjects: 45
Study 36168678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore-Tex® thyroplasty (both groups combined)
Number of subjects: 45
Study 33719474 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 120
Study 33719474 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 32862469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous eptinezumab 100 mg
Number of subjects: 0
Study 32862469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous eptinezumab 300 mg
Number of subjects: 0
Study 32862469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32862469 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchor-based methods for item-level analyses
Number of subjects: 0
Study 34633168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 126
Study 34633168 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 126
Study 34633168 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study 33486817 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational handbook in addition to standard AD management
Number of subjects: 175
Study 33486817 — intervention group
Group type: COMPARATOR
Intervention: Standard management alone
Number of subjects: 175
Study 35258533 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologically focused CPR training at the point of care and structured clinical event debriefings; 48 trainings/unit per month and 1 debriefing/unit per month
Number of subjects: 1129
Study 35258533 — intervention group
Group type: COMPARATOR
Intervention: Usual pediatric ICU management of cardiac arrest
Number of subjects: 1129
Study 34763335 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 60
Study 34763335 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 60
Study 32593750 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 15
Study 32593750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 15
Study 34839056 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immersive VR-based serious games (15 sessions, 45 min, 5 times per week)
Number of subjects: 56
Study 34839056 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immersive VR-based serious games
Number of subjects: 56
Study 34839056 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training (15 sessions, 45 min, 5 times per week)
Number of subjects: 56
Study 33741668 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training consisting of three weekly exercise sessions
Number of subjects: 220
Study 33741668 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counselling supported by health technology
Number of subjects: 220
Study 33741668 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 220
Study 33741668 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 220
Study 32051195 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal/Fast nicotine metabolizers
Number of subjects: 0
Study 32051195 — intervention group
Group type: COMPARATOR
Intervention: Slow nicotine metabolizers
Number of subjects: 0
Study 34353294 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence-focused guidance (AFG)
Number of subjects: 404
Study 34353294 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help (SH)
Number of subjects: 404
Study 34353294 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 404
Study 32301053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic combined exercise (24-week, three times weekly, moderate-intensity)
Number of subjects: 47
Study 32301053 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 47
Study 35196310 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtually Augmented Self-Hypnosis (VA-HYPO)
Number of subjects: 100
Study 35196310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VA-HYPO)
Number of subjects: 100
Study 32773365 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AG)
Number of subjects: 54
Study 32773365 — intervention group
Group type: COMPARATOR
Intervention: Breathing Exercises (BG)
Number of subjects: 54
Study 34452729 — intervention group
Group type: EXPERIMENTAL
Intervention: LiFT program participants
Number of subjects: 786
Study 34452729 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 786
Study 32506309 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of IBU/APAP 200 mg/500 mg
Number of subjects: 394
Study 32506309 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of IBU/APAP 250 mg/500 mg
Number of subjects: 394
Study 32506309 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of IBU/APAP 300 mg/500 mg
Number of subjects: 394
Study 32506309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 394
Study 32506309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 35166009 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10/25 mg/day)
Number of subjects: 7020
Study 35166009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 35166009 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 33130153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cognitive behavioral therapy (ADAPT) plus medical treatment as usual
Number of subjects: 139
Study 33130153 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment as usual only
Number of subjects: 139
Study 35909479 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior auricular injection (retroauricular group)
Number of subjects: 46
Study 35909479 — intervention group
Group type: COMPARATOR
Intervention: Tympanum injection (tympanic group)
Number of subjects: 46
Study 33988940 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term spinal cord stimulation (stSCS)
Number of subjects: 96
Study 33988940 — intervention group
Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 96
Study 32777605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led proactive self-care program
Number of subjects: 457
Study 32777605 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 457
Study 36519447 — intervention group
Group type: EXPERIMENTAL
Intervention: vancomycin‐preceded FMT, N = 24
Number of subjects: 64
Study 36519447 — intervention group
Group type: COMPARATOR
Intervention: vancomycin, N = 16
Number of subjects: 64
Study 36519447 — intervention group
Group type: COMPARATOR
Intervention: fidaxomicin, N = 24
Number of subjects: 64
Study 34126641 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Thalamic Stimulation (ANT DBS)
Number of subjects: 0
Study 32314939 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA) with continuous postoperative epidural analgesia
Number of subjects: 44
Study 32314939 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with patient‐controlled intravenous analgesia
Number of subjects: 44
Study 32314939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SA and GA
Number of subjects: 44
Study 36141488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact training (G1)
Number of subjects: 39
Study 36141488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact training + calcium and vitamin D intake (G2)
Number of subjects: 39
Study 36141488 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at an intense pace + calcium and vitamin D (G3)
Number of subjects: 39
Study 32949463 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity to Echinococcus granulosus
Number of subjects: 305
Study 32949463 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 305
Study 32949463 — intervention group
Group type: EXPERIMENTAL
Intervention: Locality
Number of subjects: 305
Study 32949463 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with dogs
Number of subjects: 305
Study 35761343 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent nurse-led family support intervention
Number of subjects: 896
Study 35761343 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 896
Study 33539749 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐course radiotherapy followed by chemotherapy before total mesorectal excision (TME)
Number of subjects: 0
Study 33539749 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy
Number of subjects: 0
Study 32723668 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective exercise program for 8 weeks, 30 min/d, 3 days per week
Number of subjects: 32
Study 35286849 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA‐AT
Number of subjects: 90
Study 35286849 — intervention group
Group type: COMPARATOR
Intervention: Placebo+Therapy
Number of subjects: 90
Study 34595804 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fluids
Number of subjects: 470
Study 34595804 — intervention group
Group type: COMPARATOR
Intervention: No IV fluids
Number of subjects: 470
Study 35537094 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based and mobile HIV‐testing campaigns in intervention communities
Number of subjects: 18597
Study 32179448 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab arm (n=23)
Number of subjects: 49
Study 32179448 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (n=26)
Number of subjects: 49
Study 32179448 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for all patients
Number of subjects: 49
Study 36052360 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen 10 mg kg−1
Number of subjects: 95
Study 36052360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 95
Study 35862389 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% recommended dose of fertilizer (RDF) with planting in the first week of October
Number of subjects: 0
Study 35862389 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% recommended dose of fertilizer (RDF) with planting in the second week of October
Number of subjects: 0
Study 35862389 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% recommended dose of fertilizer (RDF) with planting in the first week of October
Number of subjects: 0
Study 35862389 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% recommended dose of fertilizer (RDF) with planting in the first week of October
Number of subjects: 0
Study 35862389 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% recommended dose of fertilizer (RDF) with planting in the first fortnight of October
Number of subjects: 0